We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Mr. Gene: Launch of the Worldwide First B2B eCommerce Platform for Genetic Engineering

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

GENEART AG has launched 'Mr. Gene' as a second GENEART AG brand. Using the Mr. Gene Internet platform customers can design gene sequences to fit their project plans and then directly order these gene sequences online.

The automated eCommerce platform ensures an attractive price/value ratio. This eCommerce solution provides easy access to synthetic genes especially for scientists from the academic world. The production of synthetic genes now definitely replaces past laborious cloning strategies, and the resulting gene constructs exactly match the customer's project requirements.

From now on however, fully automated Mr. Gene eCommerce platform offers the opportunities to process pure gene synthesis orders online and to optimize genes in a do-it-yourself process at an attractive price. Particularly targeting academic customers, the eCommerce platform favorably positions Mr. Gene in the emerging low-price market for the standardized production of synthetic genes.

The GENEART AG was able to significantly lower the costs of producing synthetic genes through skillful use of automation and miniaturization. Step by step and as a result of these innovations, the production of synthetic genes has replaced the classical genetic engineering methods and has emerged from a niche application to a standard tool in the pharmaceutical and biotechnological industries.

Professor Wagner, CSO of the GENEART AG, elucidates: "The use of synthetic genes in modern biotechnology offers scientists a high level of flexibility. Therefore, universities and public research institutes now also show a strongly growing demand for competitively priced synthetic genes. We are delighted that Mr. Gene will now bring many advantages of using synthetic genes to academic research groups as well."

Christian Ehl, CFO of the GENEART AG, comments: "Mr. Gene as a second brand is our answer to the anticipated strong sales growth in this market segment. Our medium term projections put the Mr. Gene sales at 25 percent of the GENEART sales. The operating margin for Mr. Gene products will be equally attractive thanks to the high level of automation using the eCommerce platform."